small nuclear ribonucleoprotein polypeptide C pseudogene 17Genealiases: []
Q-omics provides the consensus-scored SNRPCP17 profile across patient tissues and cancer cell-line models. SNRPCP17 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNRPCP17 is differentially expressed in 3, with the highest sampling consensus in LUSC. Additionally, SNRPCP17 RNA expression shows 4,642 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, LUSC, and STAD as cancer lineages where SNRPCP17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNRPCP17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNRPCP17 survival associations across molecular data types. SNRPCP17 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNRPCP17 RNA expression–survival associations across cancer types. High SNRPCP17 expression shows unfavorable associations in UVM, COAD, TGCT and STAD, but favorable associations in KIRC and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .013). Together, the overview and detailed table identify KIRC as the clearest survival context for SNRPCP17 RNA expression.
This table summarizes SNRPCP17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for SNRPCP17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNRPCP17 shows lower tumor expression in LUSC, KICH and THCA. The LUSC box plot shows higher SNRPCP17 RNA expression in normal versus tumor tissue (log2 FC = −0.430, t-test p = .002).
This table shows molecular features associated with SNRPCP17 in patient tissues and cancer cell lines. In patient samples, SNRPCP17 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
